X0508 4 2025-12-08 0001133416 GALECTIN THERAPEUTICS INC GALT 0001557082 Shlevin Harold H. C/O GALECTIN THERAPEUTICS INC. 4960 PEACHTREE INDUSTRIAL BLVD., STE 240 NORCROSS GA 30071 true false false false true Common Stock 2025-12-08 4 S false 4000 6.005 D 11206 D Common Stock 2025-12-08 4 M false 35000 2.86 A 46206 D Common Stock 2025-12-08 4 S false 35000 5.95 D 11206 D Common Stock 2025-12-08 4 M false 20000 2.11 A 31206 D Common Stock 2025-12-08 4 S false 20000 5.962 D 11206 D Common stock 2025-12-08 4 M false 20000 1.98 A 31206 D Common stock 2025-12-08 4 S false 20000 5.962 D 11206 D Common Stock 2025-12-08 4 M false 25000 1.72 A 36206 D Common Stock 2025-12-08 4 S false 25000 5.946 D 11206 D Common Stock 2025-12-08 4 M false 35000 2.11 A 46206 D Common Stock 2025-12-08 4 S false 35000 6.019 D 11206 D Common Stock 2025-12-08 4 M false 20000 1.11 A 31206 D Common Stock 2025-12-08 4 S false 20000 6.002 D 11206 D Common Stock 2025-12-09 4 M false 16790 4.16 A 27996 D Common Stock 2025-12-09 4 S false 16790 6.266 D 11206 D Stock option (right to buy) 2.86 2025-12-08 4 M false 35000 0 D 2021-12-31 2031-03-25 Common Stock 35000 35000 D Stock option (right to buy) 2.11 2025-12-08 4 M false 20000 0 D 2021-12-31 2031-03-25 Common Stock 20000 20000 D Stock option (right to buy) 1.98 2025-12-08 4 M false 20000 0 D 2022-12-31 2032-01-24 Common stock 20000 20000 D Stock Option (right to buy) 1.72 2025-12-08 4 M false 25000 0 D 2024-12-31 2034-01-24 Common Stock 25000 25000 D Stock Option (right to buy) 2.11 2025-12-08 4 M false 35000 0 D 2024-12-31 2031-03-25 Common Stock 35000 35000 D Stock Option (right to buy) 1.11 2025-12-08 4 M false 20000 0 D 2023-12-31 2033-01-26 Common Stock 20000 20000 D Stock Option (right to buy) 4.16 2025-12-09 4 M false 16790 0 D 2018-12-31 2028-05-22 Common Stock 16790 73210 D The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025. The options vested as follows: 25% on each of June 30, 2021, December 31, 2021, June 30, 2022, and December 31, 2022. The options vested 100% on December 31, 2021. The options vested 100% on December 31, 2022. The options vested 100% on December 31, 2024. The options vested 100% on December 31, 2023. The shares were sold in multiple transactions at prices ranging from $6.00 to $6.05. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. The shares were sold in multiple transactions at prices ranging from $5.69 to $6.05. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. The shares were sold in multiple transactions at prices ranging from $5.69 to $6.034. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. The shares were sold in multiple transactions at prices ranging from $6.00 to $6.08. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. The options vested as follows: 25% on each of June 30, 2018 and September 30, 2018, and 50% on December 31, 2018. The shares were sold in multiple transactions at prices ranging from $6.25 to $6.31. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Jack W. Callicutt, by power of attorney 2025-12-10